Mini Review ARTICLE
Epigenetic-transcriptional regulation of fatty acid metabolism and its alterations in leukaemia
- 1Josep Carreras Leukaemia Research Institute, Spain
- 2Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Spain
In recent years fatty acid metabolism has gained greater attention in haematologic cancers such as acute myeloid leukaemia. The oxidation of fatty acids provides fuel in the form of ATP and NADH, while fatty acid synthesis provides building blocks for cellular structures. Here, we will discuss how leukaemic cells differ from healthy cells in their increased reliance on fatty acid metabolism. In order to understand how these changes are achieved, we describe the main pathways regulating fatty acid metabolism on the transcriptional level and highlight the limited knowledge about related epigenetic mechanisms. We explore these mechanisms in the context of leukaemia and consider the relevance of the bone marrow microenvironment in disease management. Finally we discuss efforts to interfere with fatty acid metabolism as a therapeutic strategy along with the use of metabolic parameters as biomarkers.
Keywords: Cancer, AML – acute myeloid leukaemia, fatty acid metabolism, Fatty acid oxidation (FAO), epigenetics, CPT1, transcription
Received: 29 Jun 2018;
Accepted: 03 Sep 2018.
Edited by:Carles Canto, Nestle Institute of Health Sciences (NIHS), Switzerland
Reviewed by:Davide Gabellini, San Raffaele Hospital (IRCCS), Italy
Beisi Xu, St. Jude Children's Research Hospital, United States
Copyright: © 2018 Maher, Diesch, Casquero Galindo and Buschbeck. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Marcus Buschbeck, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, firstname.lastname@example.org